<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04413409</url>
  </required_header>
  <id_info>
    <org_study_id>FUSCC-OMIT</org_study_id>
    <nct_id>NCT04413409</nct_id>
  </id_info>
  <brief_title>A Trial Evaluating the Efficacy of Metastasectomy in Patients With Oligo-Metastatic Breast Cancer(OMIT)</brief_title>
  <official_title>A Trial Evaluating the Efficacy of Metastasectomy in Patients With Oligo-Metastatic Breast Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fudan University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Fudan University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a randomized clinical trial (OMIT study) evaluating the efficacy of metastasectomy in
      patients with oligo-metastatic breast cancer.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 10, 2019</start_date>
  <completion_date type="Anticipated">March 10, 2025</completion_date>
  <primary_completion_date type="Anticipated">March 10, 2023</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Overall Survival</measure>
    <time_frame>3-year</time_frame>
    <description>Overall survival is calculated from randomization to death from any cause</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time To Event (TTE)</measure>
    <time_frame>From date of randomization at baseline to the time of the first event, assessed up to 60 months</time_frame>
    <description>From date of randomization at baseline to the time of the first event (Disease progression, local recurrence or distant metastasis, contralateral breast cancer, second primary tumor, or death from any cause), whichever came first, assessed up to 60 months</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">172</enrollment>
  <condition>Breast Cancer</condition>
  <arm_group>
    <arm_group_label>surgical group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The metastatic sites are firstly treated by surgery then followed by systemic treatment</description>
  </arm_group>
  <arm_group>
    <arm_group_label>systemic group</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>After confirmation of puncture, receive systemic treatment</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Metastasectomy for the metastatic sites</intervention_name>
    <description>patients randomized to this group will receive metastasectomy for the metastatic sites then followed by the systemic therapy</description>
    <arm_group_label>surgical group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. women aged 18-70 years old;

          2. ECOG score: 0-2 points;

          3. the expected life period is more than 3 months;

          4. Histologically confirmed metastatic breast cancer: locations include central lung
             lesions, peripheral lung lesions or liver metastases;

          5. PET-CT or other imaging showed patients with ≤3 metastastatic sites, involving 1-2
             organs mentioned above, single lesion ≤5cm;

          6. according to the RECIST 1.1 edition, there is at least one measurable lesion;

          7. the main organs are functioning normally, meeting the following criteria: Blood
             routine: Hb &gt; 90g/L (no blood transfusion within 14 days); ANC &gt; 1.5 x 109/L; PLT &gt; 75
             * 109/L;Liver function: total bilirubin TBIL is less than 1.5 x ULN (upper limit of
             normal value); ALT and AST are less than 3 x ULN; if there is liver metastasis, ALT
             and AST are less than 5 x ULN;Renal function: serum creatinine &lt; 1 x ULN;

          8. participants voluntarily joined the study, signed informed consent, and followed up.

        Exclusion Criteria:

          1. the number of metastastatic sites ≥ 3, or the surgeon determines that the R0 resection
             cannot be achieved;

          2. with metastatic lesions other than liver or lung

          3. patients with local recurrence

          4. palliative radiation therapy or interventional therapy have been performed previously
             for metastatic lesions

          5. has received systemic treatment for metastatic disease, such as chemotherapy, targeted
             therapy, endocrine therapy, immunotherapy, etc.

          6. pregnant or lactating women, women of childbearing age who cannot practice effective
             contraceptives;

          7. involvement in clinical trials of unlisted drugs within 4 weeks before the start of
             this study;

          8. severe cardiopulmonary insufficiency, severe liver and kidney insufficiency;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <gender_based>Yes</gender_based>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>ZhiMin Shao, MD, PhD</last_name>
    <phone>+86-21-64175590</phone>
    <phone_ext>8808</phone_ext>
    <email>zhimingshao@yahoo.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Fudan University Shanghai Cancer Center</name>
      <address>
        <city>Shanghai</city>
        <zip>200032</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>zhimin shao</last_name>
      <phone>+86-21-64175590</phone>
      <phone_ext>8808</phone_ext>
      <email>zhimingshao@yahoo.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>June 2020</verification_date>
  <study_first_submitted>March 7, 2020</study_first_submitted>
  <study_first_submitted_qc>June 1, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">June 4, 2020</study_first_posted>
  <last_update_submitted>June 1, 2020</last_update_submitted>
  <last_update_submitted_qc>June 1, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">June 4, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Fudan University</investigator_affiliation>
    <investigator_full_name>Zhimin Shao</investigator_full_name>
    <investigator_title>Chief Physician</investigator_title>
  </responsible_party>
  <keyword>metastasectomy</keyword>
  <keyword>oligo-metastatic breast cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

